227 related articles for article (PubMed ID: 10929797)
1. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
Moritz S; Krausz M; Gottwalz E; Andresen B
Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia.
Cohen JD; Van Putten T; Marder S; Berger PA; Stahl SM
J Clin Psychopharmacol; 1987 Oct; 7(5):324-9. PubMed ID: 2890671
[TBL] [Abstract][Full Text] [Related]
3. Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia.
Krausz M; Moritz S; Lambert M; Naber D
Int Clin Psychopharmacol; 2000 Mar; 15(2):77-81. PubMed ID: 10759338
[TBL] [Abstract][Full Text] [Related]
4. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
Kinon BJ; Kane JM; Chakos M; Munne R
Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
[TBL] [Abstract][Full Text] [Related]
5. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
[TBL] [Abstract][Full Text] [Related]
6. [Testing basic visual functions in the evaluation of extrapyramidal side effects of antipsychotic agents].
Kéri S; Antal A; Szekeres G; Szendi I; Kovács Z; Janka Z; Benedek G
Orv Hetil; 1998 Feb; 139(5):235-8. PubMed ID: 9489377
[TBL] [Abstract][Full Text] [Related]
7. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects.
Taira M; Hashimoto T; Takamatsu T; Maeda K
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1139-42. PubMed ID: 16765499
[TBL] [Abstract][Full Text] [Related]
8. Extrapyramidal side effects: a historical perspective.
Rifkin A
J Clin Psychiatry; 1987 Sep; 48 Suppl():3-6. PubMed ID: 2887555
[TBL] [Abstract][Full Text] [Related]
9. Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis.
Singh MM; Kay SR
Biol Psychiatry; 1979 Apr; 14(2):277-94. PubMed ID: 38865
[TBL] [Abstract][Full Text] [Related]
10. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Kim JH; Byun HJ
J Clin Pharm Ther; 2007 Oct; 32(5):461-7. PubMed ID: 17875112
[TBL] [Abstract][Full Text] [Related]
11. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status.
Putzhammer A; Perfahl M; Pfeiff L; Hajak G
Pharmacopsychiatry; 2005 May; 38(3):132-8. PubMed ID: 15902585
[TBL] [Abstract][Full Text] [Related]
12. Zotepine, a neuroleptic drug with a bipolar therapeutic profile.
Dieterle DM; Ackenheil M; Müller-Spahn F; Kapfhammer HP
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):52-7. PubMed ID: 2883683
[TBL] [Abstract][Full Text] [Related]
13. Prolactin response and extrapyramidal side effects during propranolol and neuroleptic drugs treatment in chronic schizophrenic patients.
Elizur A; Segal S; Yeret A; Ben-David M
Isr Ann Psychiatr Relat Discip; 1979 Dec; 17(4):318-27. PubMed ID: 44877
[No Abstract] [Full Text] [Related]
14. Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics?
Henkel V; Mergl R; Schäfer M; Rujescu D; Möller HJ; Hegerl U
Pharmacopsychiatry; 2004 May; 37(3):110-8. PubMed ID: 15138894
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of schizophrenia].
Houy-Durand E; Thibaut F
Rev Prat; 2002 Jun; 52(11):1213-20. PubMed ID: 12148207
[TBL] [Abstract][Full Text] [Related]
16. Neuroleptic drug utilisation for acute schizophrenia.
Razali MS; Hasanah CI
Singapore Med J; 1996 Dec; 37(6):611-3. PubMed ID: 9104062
[TBL] [Abstract][Full Text] [Related]
17. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms.
Taniguchi T; Sumitani S; Aono M; Iga J; Kinouchi S; Aki H; Matsushita M; Taniguchi K; Tsuno M; Yamanishi K; Tomotake M; Kaneda Y; Ohmori T
Hum Psychopharmacol; 2006 Oct; 21(7):439-45. PubMed ID: 17029303
[TBL] [Abstract][Full Text] [Related]
18. [Non-extrapyramidal motor side-effects in long-term therapy with neuroleptics: an analysis of 99 patients].
Ginzel I; Hilger E; Barnas C
Wien Klin Wochenschr; 2002 Jan; 114(1-2):38-43. PubMed ID: 12407934
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
20. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
Reschke RW
Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
